Combined Metformin and Baricitinib Therapy Attenuates Inflammation in <scp>STZ</scp> ‐Induced Diabetic Rats via <scp>AMPK</scp> / <scp>JAK</scp> – <scp>STAT</scp> Pathway Crosstalk
Our results suggest that the coadministration of metformin with baricitinib reduces insulin resistance, improves histopathological alterations in the liver and pancreatic islet cells and counteracts the adverse effects of baricitinib on the lipid profile in diabetic rats. These findings hold particular significance for patients undergoing baricitinib treatment.
Authors
- Mehrdad Jahanshahi (ORCID: https://orcid.org/0000-0001-8845-6018)
- Abdoljalal Marjani (ORCID: https://orcid.org/0000-0003-2826-5951)
- Marie Saghaeian Jazi (ORCID: https://orcid.org/0000-0003-0647-9545)
- Mostafa Allahyari (ORCID: https://orcid.org/0000-0002-1569-5015)
Institutions
- Golestan University (IR)
- Golestan University of Medical Sciences (IR)
Publication Details
- Journal
- Endocrinology Diabetes & Metabolism
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/edm2.70101
- Primary Topic
- Adipokines, Inflammation, and Metabolic Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Golestan University of Medical Sciences